Vascular Dementia Market

DelveInsight’s ‘Vascular Dementia (VaD)-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Vascular Dementia (VaD), historical and forecasted epidemiology as well as the Vascular Dementia (VaD) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The VaD market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM VaD market size from 2019 to 2032. The Report also covers current VaD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Vascular Dementia (VaD) Disease Understanding and Treatment Algorithm

Vascular Dementia (VaD) Overview

The word dementia describes a set of symptoms that can include memory loss and difficulties with thinking, problem-solving, or language. In vascular dementia, these symptoms occur when the brain is damaged because of problems with blood supply to the brain. Vascular dementia (VaD) is an etiological category of dementia characterized by severe cognitive impairment resulting from ischemic or hemorrhagic stroke or hypoperfusion affecting brain regions important for memory, cognition, and behavior. Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients. Cognition and brain function can be significantly affected by the size, location, and the number of vascular changes.

 

A growing number of experts prefer the term “vascular cognitive impairment” (VCI) to “vascular dementia” because they feel it better expresses the concept that vascular thinking changes can range from mild to severe. According to the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) guideline, VaD can be classified into four major subtypes: Post-stroke dementia (PSD) defined as dementia manifesting within 6 months after a stroke; Subcortical ischemic vascular dementia (SIVAD); Multi-infarct (cortical) dementia; and mixed dementia.

 

VaD is caused by different conditions that interrupt the flow of blood and oxygen supply to the brain and damage blood vessels in the brain.

 

Vascular Dementia (VaD) Diagnosis

The diagnosis of vascular dementia should be suspected in patients with significant vascular risk factors, stroke, or heart disease who exhibit abrupt changes in cognition. Brain imaging demonstrating the presence of relevant lesions of cerebrovascular disease is crucial for diagnosing vascular dementia.

Continued in the report…..

 

Vascular Dementia (VaD) Treatment

In Vascular dementia decreased blood flow damages brain tissue. Blood flow to brain tissue may be reduced by a partial blockage or completely blocked by a blood clot. Currently, there is no cure for the condition or a way to reverse the damage already happened. But, treatment can help prevent further damage to the brain in people with vascular dementia and may slow down its progression.

 

The progress in the understanding of vascular cognitive impairment (VCI) and vascular dementia (VaD) has resulted in the development of promising symptomatic and preventive treatments. The primary prevention of treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors. This can be achieved by addressing the vascular risk factors, including arterial hypertension, lipid abnormalities, atrial fibrillation, myocardial infarction, coronary heart disease, diabetes, atherosclerosis, smoking, and hyperhomocysteinemia.

 

Secondary prevention may include management of stroke and prevention, by early diagnosis and appropriate treatment of acute stroke; prevention of stroke recurrence; and slowing of progression of brain changes associated with VaD by intensive management of existing risk factors.

 

The treatment goal includes symptomatic improvement of the core symptoms such as cognition, function, and behavior; slowing of progression of disease; and treatment of neuropsychiatric symptoms such as depression, anxiety, and others.

Continued in the report…..

Vascular Dementia (VaD) Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of dementia, diagnosed prevalent cases of dementia, diagnosed prevalent cases of vascular dementia and age-specific diagnosed prevalent cases of vascular dementia in scenario of Vascular Dementia (VaD) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • As per the assessment of DelveInsight, total prevalent cases of dementia in the 7MM were found to be 21,591,565 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 2.42% during study period.
  • The diagnosed prevalent cases of dementia in the 7MM were found to be 11,344,408 in 2021, which are expected to increase at a CAGR of 3.60% for the study period of 2019-2032.
  • As per DelveInsight estimates, 7MM accounts for 2,795,390 diagnosed prevalent cases of VaD in 2021, which are expected to increase at a CAGR of 3.60%.
  • Among 7MM, the United States has the highest diagnosed cases of VaD with 1,110,606 cases in 2021, equivalent to 40% of total diagnosed prevalent cases in the 7MM.
  • Vascular Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare. Thus, we have stratified diagnosed prevalence cases in the age group of 60–70 years, 71–80 years, 81–90 years, and ≥91 years.
  • In 2021, the EU-5 accounts for 893,124 diagnosed prevalent cases of VaD, which will increase by 2032 at a CAGR of 3.26%.
  • In 2021, Japan had 791,660 diagnosed cases of VaD ranking second-highest among 7MM. These cases are expected to increase by 2032 at a CAGR of 3.37% during the forecasted period (2022–2032).

Country-Wise Vascular Dementia (VaD) Epidemiology

The epidemiology segment also provides the Vascular Dementia (VaD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Vascular Dementia (VaD) Drug Chapters

The drug chapter segment of the Vascular Dementia (VaD) report encloses the detailed analysis of Vascular Dementia (VaD) mid-phase, and late-stage pipeline drugs. It also helps to understand the Vascular Dementia (VaD) clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of each included drug and the latest news and press releases.

 

Vascular Dementia (VaD) Emerging Drugs

 

BAC: Charsire Biotechnology Corp

BAC (also called CSTC1, CHARSIRE Trauma Complex 1), a component of soybean extraction developed by Charsire Biotechnology Corp, is under investigation to treat a variety of diseases, including AD and VaD. BAC is a vapor fraction from seeds of Glycine max (L.) Merr. BAC in its studies showed to promote the proliferation of neuroblastoma IMR-32 cells, and this observation may correlate to the improvement of the cognitive performance in the heavy metal-induced AD mice and the VaD-resembled rats when treated with BAC.

Products detail in the report…

 

PNA1: ProNeurogen Therapeutics

PNA1, a rationally-designed Angiotensin-(1-7) Mas receptor agonists that have enhanced BBB penetration half-life and designed to inhibit chronic inflammatory pathways in both the brain and the cerebrovasculature endothelium. These pathways are involved in vascular dementia and neuropathic pain. These novel peptide formulations are designed to act on Mas receptors (MasR) within the brain vascular endothelium and neuronal cells and microglia to decrease brain ROS production and neuroinflammation. The drug candidate is based on technology developed at the University of Arizona.

Products detail in the report…

List to be continued in the report…

Vascular Dementia (VaD) Market Outlook

Vascular dementia is a common condition with no effective approved pharmacological treatments available. Vascular dementia (VaD) arises from ischemic insults such as hemorrhage and hypoperfusion that trigger neurodegeneration by depriving nerve cells of oxygen and glucose.

 

VaD has multifactorial etiopathology, diverse clinical manifestations, and multiple clinical subtypes. Moreover, the diagnostic criteria are not consistent worldwide.

 

Although patients with VaD constitute the second-largest dementia population, treatment data are lacking. There are no effective pharmacological compounds approved for the treatment of vascular dementia in any jurisdiction worldwide. Controlling medical conditions that impact cardiovascular health is recommended to prevent further decline. For example, medications can be prescribed to control blood pressure, cholesterol, heart disease, and diabetes. Aspirin or other drugs may be prescribed to prevent clots from forming in blood vessels

 

According to DelveInsight, Vascular Dementia (VaD) treatment paradigm in the 7MM is expected to change during the forecasted period 2022–2032.

 

Key Findings

  • The market size of Vascular Dementia in the seven major markets is expected to increase at approximate Compound Annual Growth Rate (CAGR) of 4.05% for the study period (2019–2032) from USD 2,230 million in 2021 to significant market size by 2032.
  • Expected launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Vascular Dementia (VaD).
  • Upcoming therapies such as BAC have the potential to create a significant positive shift in the Vascular Dementia (VaD) market size.
  • The United States accounts for the largest market size of Vascular Dementia (VaD), in comparison to EU-5 (Germany, France, Italy, Spain, and the United Kingdom,) and Japan.
  • Among the EU-5 countries, Germany had the highest market size, while Spain had the lowest market size of Vascular Dementia (VaD) throughout the study period (2019–2032).

 

The United States Market Outlook

This section provides the total Vascular Dementia (VaD) market size and; market size by therapies in the United States.

 

EU-5 Market Outlook

The total Vascular Dementia (VaD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Vascular Dementia (VaD) market size and market size by therapies in Japan are provided.

Vascular Dementia (VaD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Vascular Dementia (VaD) market or expected to get launched in the market during the study period 2019–2032. The analysis covers Vascular Dementia (VaD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Vascular Dementia (VaD) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Vascular Dementia (VaD) emerging therapies.

Reimbursement Scenario in Vascular Dementia (VaD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Vascular Dementia (VaD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Vascular Dementia (VaD), explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Vascular Dementia (VaD) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Vascular Dementia (VaD) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Vascular Dementia (VaD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Vascular Dementia (VaD) market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Vascular Dementia (VaD) market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia (VaD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Vascular Dementia (VaD). Launch of emerging therapies will significantly impact the Vascular Dementia (VaD) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Vascular Dementia (VaD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Vascular Dementia (VaD) Pipeline Analysis
  • Vascular Dementia (VaD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Vascular Dementia (VaD) Report Key Strengths

  • 11-Years Forecast
  • 7MM Coverage
  • Vascular Dementia (VaD) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Vascular Dementia (VaD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Vascular Dementia (VaD) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Vascular Dementia (VaD) total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Vascular Dementia (VaD) market size during the forecast period (2022–2032)?
  • At what CAGR, the Vascular Dementia (VaD) market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Vascular Dementia (VaD) market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Vascular Dementia (VaD) market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Vascular Dementia (VaD)?
  • What is the historical Vascular Dementia (VaD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Vascular Dementia (VaD) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Vascular Dementia (VaD)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Vascular Dementia (VaD) during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Vascular Dementia (VaD)?
  • What are the current treatment guidelines for the treatment of Vascular Dementia (VaD) in the US and Europe?
  • How many companies are developing therapies for the treatment of Vascular Dementia (VaD)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Vascular Dementia (VaD)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia (VaD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Vascular Dementia (VaD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Vascular Dementia (VaD)?
  • What are the 7MM historical and forecasted market of Vascular Dementia (VaD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Vascular Dementia (VaD).
  • To understand the future market competition in the Vascular Dementia (VaD) market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Vascular Dementia (VaD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Vascular Dementia (VaD) market.
  • To understand the future market competition in the Vascular Dementia (VaD) market.

1. Key Insights

2. Report Introduction

3. Vascular Dementia Market Overview at a Glance

3.1. Market Share (%) Distribution of Vascular Dementia by Therapies in 2019

3.2. Market Share (%) Distribution of Vascular Dementia by Therapies in 2032

4. Vascular Dementia Market: Future Perspective

5. Executive Summary of Vascular Dementia

6. Key Events

7. Disease Background and Overview

7.1. Introduction of Vascular dementia

7.2. Classification of Vascular dementia

7.3. Causes and risk factors of Vascular dementia

7.4. Signs and Symptoms of Vascular dementia

7.5. Pathophysiology of Vascular dementia

7.6. Diagnosis of Vascular dementia

7.6.1. Diagnostic Guidelines of Vascular dementia

7.6.1.1. American Heart Association/American Stroke Association

7.6.1.2. National Institute for Health and Care Excellence Guidelines

7.7. Treatment and Management of Vascular dementia

7.7.1. Treatment Guidelines

7.7.1.1. Guideline from the American College of Physicians and the American Academy of Family Physicians

7.7.1.2. EFNS-ENS Guidelines

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: 7MM

8.3.1. The United States

8.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.3.3. Japan

8.4. Total Diagnosed Prevalent Cases of Dementia in the 7MM

8.5. Total Diagnosed Prevalent Cases of Vascular Dementia in the 7MM

8.6. The United States

8.6.1. Prevalent Cases of Dementia in the United States

8.6.2. Diagnosed Prevalent Cases of Dementia in the United States

8.6.3. Diagnosed Prevalent Cases of Vascular Dementia in the United States

8.6.4. Age-specific Diagnosed Prevalent Cases of Vascular Dementia in the United States

8.7. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.7.1. Prevalent Cases of Dementia in EU-5

8.7.2. Diagnosed Prevalent Cases of Dementia in EU-5

8.7.3. Diagnosed Prevalent Cases of Vascular Dementia in EU-5

8.7.4. Age-specific Diagnosed Prevalent Cases of Vascular Dementia in EU-5

8.8. Japan

8.8.1. Prevalent Cases of Dementia in Japan

8.8.2. Diagnosed Prevalent Cases of Dementia in Japan

8.8.3. Diagnosed Prevalent Cases of Vascular Dementia in Japan

8.8.4. Age-specific Diagnosed Prevalent Cases of Vascular Dementia in Japan

9. Patient Journey

10. Emerging Drugs

10.1. Key Cross Competition

10.2. BAC: Charsire Biotechnology Corp.

10.2.1. Product Description

10.2.2. Development activities

10.2.3. Clinical Development

10.2.4. Clinical Trials Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.3. PNA1: ProNeurogen Therapeutics

10.3.1. Product Description

10.3.2. Development activities

10.3.3. Product Profile

10.4. Apabetalone: Resverlogix Corp.

10.4.1. Product Description

10.4.2. Development activities

10.4.3. Clinical Development

10.4.4. Clinical Trials Information

10.4.5. Safety and Efficacy

10.4.6. Product Profile

11. Vascular Dementia: Seven Major Market Analysis

11.1. Key Findings

11.2. Methodology of Vascular Dementia (VaD) Market

11.3. Market Outlook

11.4. Potential of Current and Emerging Therapies

11.5. Key Market Forecast Assumptions

11.6. Market Size of Vascular Dementia in the 7MM

11.7. Market Size of Vascular Dementia by Therapies in the 7MM

11.8. Market Size of Vascular Dementia in the United States

11.8.1. Total Market Size of Vascular Dementia

11.8.2. Market Size of Vascular Dementia by Therapies

11.9. Market Size of Vascular Dementia in EU-5

11.9.1. Total Market Size of Vascular Dementia

11.9.2. Market Size of Vascular Dementia by Therapies

11.10. Market Size of Vascular Dementia in Japan

11.10.1. Total Market Size of Vascular Dementia

11.10.2. Market Size of Vascular Dementia by Therapies

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Reimbursement and Market Access

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Vascular Dementia Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Clinical Forms of Vascular Dementia According to Temporal Pattern of Presentation

Table 4: Risk Factors

Table 5: Total Diagnosed Prevalent Cases of Dementia in the 7MM (2019–2032)

Table 6: Total Diagnosed Prevalent Cases of Vascular Dementia in the 7MM (2019–2032)

Table 7: Prevalent Cases of Dementia in the US (2019–2032)

Table 8: Diagnosed Prevalent Cases of Dementia in the US (2019–2032)

Table 9: Diagnosed Prevalent Cases of Vascular Dementia in the US (2019–2032)

Table 10: Age-specific Diagnosed Prevalent Cases of Vascular Dementia in the US (2019–2032)

Table 11: Prevalent Cases of Dementia in EU-5 (2019–2032)

Table 12: Diagnosed Prevalent Cases of Dementia in EU-5 (2019–2032)

Table 13: Diagnosed Prevalent Cases of Vascular Dementia in EU-5 (2019–2032)

Table 14: Age-specific Diagnosed Prevalent Cases of Vascular Dementia in EU-5 (2019–2032)

Table 15: Prevalent Cases of Dementia in Japan (2019–2032)

Table 16: Diagnosed Prevalent Cases of Dementia in Japan (2019–2032)

Table 17: Diagnosed Prevalent Cases of Vascular Dementia in Japan (2019–2032)

Table 18: Age-specific Diagnosed Prevalent Cases of Vascular Dementia in Japan (2019–2032)

Table 19: Comparison of Emerging Drugs Under Development

Table 20: BAC, Clinical Trial Description, 2022

Table 21: Awards to Proneurogen by SBIR-STTR

Table 22: Apabetalone, Clinical Trial Description, 2022

Table 23: Key Market Forecast Assumptions for BAC

Table 24: Market Size of Vascular Dementia in the 7MM in USD Million (2019–2032)

Table 25: Market Size of Vascular Dementia by Therapies in the 7MM in USD Million (2019–2032)

Table 26: United States Market Size of Vascular Dementia in USD Million (2019–2032)

Table 27: Market Size of Vascular Dementia by Therapies in the US in USD Million (2019–2032)

Table 28: EU-5 Market Size of Vascular Dementia in USD Million (2019–2032)

Table 29: Market Size of Vascular Dementia by Therapies in Germany in USD Million (2019–2032)

Table 30: Market Size of Vascular Dementia by Therapies in France in USD Million (2019–2032)

Table 31: Market Size of Vascular Dementia by Therapies in Italy in USD Million (2019–2032)

Table 32: Market Size of Vascular Dementia by Therapies in Spain in USD Million (2019–2032)

Table 33: Market Size of Vascular Dementia by Therapies in the UK in USD Million (2019–2032)

Table 34: Market Size of Vascular Dementia by Therapies in the EU-5 in USD Million (2019–2032)

Table 35: Japan Market Size of Vascular Dementia in USD Million (2019–2032)

Table 36: Market Size of Vascular Dementia by Therapies in Japan in USD Million (2019–2032)

List of Figures

Figure 1: Subtypes of Dementia

Figure 2: Classification of VCI

Figure 3: Types of Vascular Dementia

Figure 4: Signs and Symptoms of Vascular dementia

Figure 5: Total Diagnosed Prevalent Cases of Dementia in the 7MM (2019–2032)

Figure 6: Total Diagnosed Prevalent Cases of Vascular Dementia in the 7MM (2019–2032)

Figure 7: Prevalent Cases of Dementia in the US (2019–2032)

Figure 8: Diagnosed Prevalent Cases of Dementia in the US (2019–2032)

Figure 9: Diagnosed Prevalent Cases of Vascular Dementia in the US (2019–2032)

Figure 10: Age-specific Diagnosed Prevalent Cases of Vascular Dementia in the US (2019–2032)

Figure 11: Prevalent Cases of Dementia in EU-5 (2019–2032)

Figure 12: Diagnosed Prevalent Cases of Dementia in EU-5 (2019–2032)

Figure 13: Diagnosed Prevalent Cases of Vascular Dementia in EU-5 (2019–2032)

Figure 14: Age-specific Diagnosed Prevalent Cases of Vascular Dementia in EU-5 (2019–2032)

Figure 15: Prevalent Cases of Dementia in Japan (2019–2032)

Figure 16: Diagnosed Prevalent Cases of Dementia in Japan (2019–2032)

Figure 17: Diagnosed Prevalent Cases of Vascular Dementia in Japan (2019–2032)

Figure 18: Age-specific Diagnosed Prevalent Cases of Vascular Dementia in Japan (2019–2032)

Figure 19: Patient Journey

Figure 20: Market Size of Vascular Dementia in the 7MM in USD Million (2019–2032)

Figure 21: Market Size of Vascular Dementia by Therapies in the 7MM in USD Million (2019–2032)

Figure 22: Market Size of Vascular Dementia in the United States, USD Millions (2019–2032)

Figure 23: Market Size of Vascular Dementia by Therapies in the US, in USD Million (2019–2032)

Figure 24: Market Size of Vascular Dementia in the EU5, USD Millions (2019–2032)

Figure 25: Market Size of Vascular Dementia by Therapies, in the EU5, in USD Million (2019–2032)

Figure 26: Market Size of Vascular Dementia in Japan, USD Millions (2019–2032)

Figure 27: Market Size of Vascular Dementia by Therapies in Japan, in USD Million (2019–2032)

Figure 28: Market Drivers

Figure 29: Market Barriers

Figure 30: SWOT Analysis

Figure 31: Unmet Needs

Charsire Biotechnology Corp
ProNeurogen Therapeutics
Resverlogix Corp.

 

Forward to Friend

Need A Quote